{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:00:00Z","timestamp":1793973600041,"version":"4.8.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011827","name":"Guangxi Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.aohep.2021.100552","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T13:23:59Z","timestamp":1633353839000},"page":"100552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus"],"prefix":"10.1016","volume":"27","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2021.100552_bib0001","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.aohep.2021.100552_bib0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1245\/s10434-012-2513-1","article-title":"A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability","volume":"20","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0003","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ejso.2019.03.042","article-title":"Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombusa multicenter study","volume":"45","author":"Xiang","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0004","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.aohep.2021.100552_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Llovet","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0006","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2021.100552_bib0007","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3350\/cmh.2016.22.1.160","article-title":"Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis","volume":"22","author":"Lee","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.aohep.2021.100552_bib0008","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiol.10101058","article-title":"Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival","volume":"258","author":"Chung","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.aohep.2021.100552_bib0009","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","article-title":"Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma","volume":"146","author":"Yau","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2021.100552_bib0010","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/cam4.1176","article-title":"Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure","volume":"6","author":"Xiang","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.aohep.2021.100552_bib0011","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2021.100552_bib0012","first-page":"499","article-title":"Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein","volume":"54","author":"Cheng","year":"2007","journal-title":"Hepato-Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100552_bib0013","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hepr.12923","article-title":"Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus","volume":"47","author":"Sakamoto","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.aohep.2021.100552_bib0014","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.aohep.2021.100552_bib0015","first-page":"637","article-title":"Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein","volume":"43","author":"Tanaka","year":"1996","journal-title":"Hepato-Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100552_bib0016","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s12094-017-1621-6","article-title":"Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma","volume":"19","author":"Xiang","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","article-title":"A new classification for hepatocellular carcinoma with portal vein tumor thrombus","volume":"18","author":"Shi","year":"2011","journal-title":"J Hepato-Biliary-Pancreatic Sci"},{"key":"10.1016\/j.aohep.2021.100552_bib0018","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.3748\/wjg.v20.i45.17141","article-title":"Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"20","author":"Ye","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.aohep.2021.100552_bib0019","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0020","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0021","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2021.100552_bib0022","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121002519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268121002519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:42:44Z","timestamp":1761648164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268121002519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1665268121002519"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100552","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2021.100552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100552"}}